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White Matter Changes Associated with Antipsychotic
Treatment in First-Episode Psychosis
Philip R Szeszko*,1,2,3, Delbert G Robinson1,2,3, Toshikazu Ikuta4, Bart D Peters1,2, Juan A Gallego1,2,3,
John Kane1,2,3 and Anil K Malhotra1,2,3
1

Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, NY, USA; 2Division of Psychiatry Research, Zucker
Hillside Hospital, North Shore-LIJ Health System, Glen Oaks, NY, USA; 3Departments of Psychiatry and Molecular Medicine, Hofstra North
Shore—LIJ School of Medicine, Hempstead, NY, USA; 4Department of Communication Sciences and Disorders, School of Applied Sciences,
University of Mississippi, University, MS, USA

Second-generation antipsychotics are utilized extensively in the treatment of psychotic disorders and other psychiatric conditions, but the
effects of these medications on human brain white matter are not well understood. We thus investigated the effects of secondgeneration antipsychotics on white matter integrity using tract-based spatial statistics in patients experiencing a first episode of psychosis
with little or no prior antipsychotic exposure, and how potential changes were associated with metabolic side effects. Thirty-five (26
men/9 women) patients experiencing a first episode of psychosis received diffusion tensor imaging (DTI) exams, clinical assessments, and
provided fasting blood samples at the onset of antipsychotic treatment, and then again after 12 weeks of treatment with either
risperidone or aripiprazole in a double-blind randomized clinical trial. In addition, 35 (26 men/9 women) healthy volunteers received DTI
exams at a baseline time point and then after 12 weeks. Patients demonstrated significant (po0.05; family-wise error corrected)
fractional anisotropy reductions within the parietal and occipital white matter following antipsychotic treatment. Greater overall fractional
anisotropy reduction was significantly correlated with greater increases in low-density lipoprotein. There were no significant fractional
anisotropy increases among patients following treatment. Moreover, healthy volunteers did not demonstrate either significant increases
or decreases in fractional anisotropy across a comparable 12-week interval. The use of antipsychotics may be associated with a subtle loss
of white matter integrity that is related to greater side effects, thus raising potentially important considerations regarding risk/benefit in
their usage. Limitations of the current study, however, include a prior history of substance use among patients and our inability to exclude
the possibility of disease progression.
Neuropsychopharmacology (2014) 39, 1324–1331; doi:10.1038/npp.2013.288; published online 19 February 2014
Keywords: diffusion tensor imaging; antipsychotic; first-episode psychosis; white matter

INTRODUCTION
Antipsychotic medications are widely prescribed not only
for the treatment of schizophrenia and related psychotic
disorders but also for a broad range of behavioral and/or
disruptive disorders in children, adolescents, and the
elderly. Thus, understanding the potential impact of
antipsychotic medications on the brain has significant
health implications. There are, however, limited longitudinal in-vivo data regarding the potential impact of
antipsychotics on the brain, and, in particular, the white
matter. Some studies suggest that antipsychotics may have
an important therapeutic role in promoting myelination
through their effects on oligodendrocytes (Walterfang et al,
2011; Bartzokis et al, 2011), with some empirical work
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suggesting a protective or myelin-inducing effect of
risperidone on the brain white matter (Bartzokis et al,
2007, 2011; Bartzokis et al, 2009). Similarly, animal studies
noted that antipsychotic treatment following administration
of the copper chelator, cuprizone, promoted oligodendrocyte development and remyelination (Xiao et al, 2008;
Zhang et al, 2012), which was evident from magnetic
resonance (MR) imaging and confirmed by histological
measures (Chandran et al, 2012). In contrast to these
studies, however, several longitudinal neuroimaging studies
reported white matter volume decreases in association with
greater exposure to antipsychotic medications (Ho et al,
2011) and white matter volume reductions in treatmentnaive patients following risperidone treatment (Molina et al,
2005; Girgis et al, 2006). Moreover, animal data report white
matter volume reductions (Dorph-Petersen et al, 2005) and,
to some extent, fewer oligodendrocytes (Konopaske et al,
2008) in macaques treated with olanzapine or haloperidol.
It is known that second-generation antipsychotics are
associated with serious side effects that significantly
increase risk for cardiometabolic disease (De Hert et al,
2011). In particular, second-generation antipsychotics have
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been linked to increased serum cholesterol and associated
abnormalities in lipid metabolism (Hoffman et al, 2010;
Bushe and Paton, 2005). However, the potential impact of
antipsychotic-induced metabolic changes on the brain white
matter has not been well investigated. This is particularly
relevant given that B25% of the total amount of cholesterol
in humans is localized to the brain, with the majority
present in myelin (Björkhem and Meaney, 2004). Although
most brain cholesterol is produced locally and the blood–
brain barrier protects it from exchange with lipoprotein
cholesterol in the circulation, it is known that antipsychotics upregulate the expression of cholesterol transport
proteins (Vik-Mo et al, 2009). Moreover, changes in
cholesterol balance across the whole body can cause
concomitant alterations in sterol recycling within the CNS
that can alter the integrity of the myelin sheath (Dietschy
and Turley, 2001). Consistent with this possibility are data
from healthy humans, indicating that elevated serum
cholesterol and, more specifically, greater low-density
lipoprotein (LDL) is associated with lower white matter
integrity among adults even below clinical thresholds for
hyperlipidemia (Williams et al, 2012).
In the current study, we prospectively investigated the
potential influence of antipsychotic medications on white
matter integrity in patients experiencing a first episode of
psychosis using longitudinal diffusion tensor imaging (DTI)
to examine whether administration of antipsychotics would
be associated with alterations in white matter integrity.
Diffusion tensor-imaging exams were conducted in the
context of a double-blind, randomized, controlled treatment
trial comparing the efficacy and tolerability of risperidone
and aripiprazole in patients experiencing a first episode of
psychosis. Given prior work (Ho et al, 2011; Molina et al,
2005; Girgis et al, 2006), we hypothesized that antipsychotic
treatment would be associated with reductions in FA, a
putative measure of white matter integrity, in patients.
Moreover, we examined the relationship between possible
white matter changes and clinical response, as well as
metabolic side effects associated with treatment.

MATERIALS AND METHODS
Subjects
Thirty-five patients experiencing a first episode of psychosis
were recruited from admissions to the inpatient service at
The Zucker Hillside Hospital in Glen Oaks, NY, and were
enrolled in an NIMH-funded double-blind, randomized
controlled trial comparing aripiprazole vs risperidone
(R01MH060004). All patients were required to have 2 weeks
or less of cumulative lifetime exposure to antipsychotics to
enter the clinical trial and received a physical exam and
laboratory screening to rule out medical causes for their
initial psychotic episode. All patient (lifetime) diagnoses
were based on the SCID for Axis I DSM-IV Disorders
supplemented by information from clinicians and, when
available, family members. First-episode patients met DSMIV criteria for schizophrenia (undifferentiated ¼ 15 and
paranoid ¼ 9), schizophreniform disorder (n ¼ 5), schizoaffective disorder (N ¼ 1), or psychosis NOS (N ¼ 5). Seventeen patients met criteria for a lifetime substance abuse/
dependence diagnosis, including (numbers in parentheses):

alcohol dependence (3), alcohol abuse (3), amphetamine
dependence (1), cannabis dependence (11), cannabis abuse
(6), cocaine dependence (2), polysubstance dependence (1),
and sedative, hypnotic, or anxiolytic abuse (1). However, in
the month preceding the baseline and follow-up scans, 8
and 3 patients, respectively, met abuse/dependence criteria.
On average, patients had a total lifetime exposure of 6.8
(SD ¼ 7.9) days of antipsychotic treatment before the baseline
scan and were scanned, on average, within 3.1 (SD ¼ 7.7)
days of entry into the clinical trial. One patient was treated
with aripiprazole for o2 weeks before the baseline scan to
meet study eligibility criteria for the clinical trial, but the
exact number of days was unavailable. Twelve patients were
antipsychotic drug naive at the time of the baseline scan.
Mean age at first psychotic symptoms was 19.0 years
(SD ¼ 3.0); data were unavailable for three patients.
In addition, we recruited 35 healthy volunteers from
advertisements posted on websites to match the demographic distributions of patients. Exclusion criteria for
healthy subjects included the presence of any lifetime history
of a major mood or psychotic disorder as determined by
clinical interview using the SCID-NP. Exclusion criteria for all
study participants included MR imaging contraindications,
neurologic conditions (Gilles de la Tourette’s, Huntington’s
disease, Parkinson’s disease, encephalitis, strokes, aneurysms,
tumors, central nervous system infections, or degenerative
brain diseases), any serious medical disorder that could affect
brain functioning or mental retardation. This study was
approved by the North Shore—Long Island Jewish Medical
Center Institutional Review Board and written informed
consent was obtained from all study participants or their
parents in the case of minors. All minors provided written
informed assent to participate in the study.

Antipsychotic Titration Schedule
Research psychiatrists followed a flexible-dosing titration
schedule. The initial daily dose for patients in the treatment
trial was 5 mg for aripiprazole and 1 mg for risperidone. The
dose was initially increased after 3 days of treatment and
then further adjustments were made every 1–3 weeks until
the patient improved, developed side effects that precluded
a dose increase, or reached a maximum daily dose of 30 mg
of aripiprazole or 6 mg of risperidone. All patients were
receiving either aripiprazole or risperidone at the time of
the second scan, except one patient who discontinued
treatment 2 weeks before the second scan. Lorazepam was
prescribed for anxiety or agitation. Patients were not
allowed to receive antidepressants or mood stabilizers, or
any other psychotropic medication. Cogentin and/or
propranolol was prescribed for extrapyramidal symptoms.

Clinical and Metabolic Assessments
Patients completed the 18-item Brief Psychiatric Rating
Scale—Anchored version (BPRS-A; Overall and Gorham,
1962) and we derived a total score by summing all items. In
addition, patients received the Schedule for Assessment of
Negative Symptoms (SANS) Zucker Hillside Clinical Trials
Version (Robinson et al, 2006), and the average of the global
measures of affective flattening, avolition, alogia, and
asociality was used as the outcome measure. Patients
Neuropsychopharmacology
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completed the clinical assessments, on average, within 3.6
(SD ¼ 7.7) and 4.6 (SD ¼ 7.0) days following the baseline
and follow-up MR imaging exams, respectively. Average
BPRS scores at the time of baseline scanning was 44.0
(SD ¼ 9.7) and 27.2 (SD ¼ 7.2) at follow-up. The average of
the global ratings from the SANS was 2.1 (SD ¼ 0.8) at
baseline and 1.8 (SD ¼ 0.6) at follow-up.
Blood samples (following all-night fasting) were drawn in
the morning for assessment of cholesterol levels, including
LDL and high-density lipoprotein (HDL). Patients completed these assessments, on average, within 1.4 (SD ¼ 8.2)
and 4.2 (SD ¼ 7.7) days following the baseline and follow-up
MR imaging exams, respectively. Total cholesterol at
baseline was 159 mg/dl (SD ¼ 24) and 174 mg/dl (SD ¼ 30)
at follow-up. LDL and HDL values at baseline were 91 mg/dl
(SD ¼ 23) and 52 mg/dl (SD ¼ 12), respectively, and at
follow-up were 102 mg/dl (SD ¼ 24) and 52 mg/dl
(SD ¼ 13), respectively. Complete data were unavailable
for four patients.

standard brain for cross subject comparisons at the voxel
level.
We used clusters that demonstrated FA reductions from
the baseline to the follow-up time points among patients in
the TBSS analysis as seed regions for tractography analysis
(Behrens et al, 2007). Using the BEDPOSTX tool, the local
(ie, within voxel) probability density functions of the
principal diffusion direction were estimated using Markov
chain Monte Carlo sampling; a spatial probability density
function across voxels was then estimated based on these
local probability density functions using the probtrackx
tool. The parameters for PROBTRACKX included: number
of samples ¼ 5000, curvature threshold ¼ 0.2, step
length ¼ 0.5 mm, and number of steps per sample ¼ 2000.
Tractography was conducted in native DTI space, and
resultant pathways were linearly registered into FMRIB FA
brain and averaged across all participants for visualization
of the ‘average’ pathway(s) passing through the seed
region(s).

Handedness

Statistical Analysis

All individuals completed a modified version of the
Edinburgh Inventory. The total number of right- and lefthand items was scored and the laterality quotient was
computed according to the following formula: (Total R 
Total L)/(Total R þ Total L) yielding a range from þ 1.00
(totally dextral) to  1.00 (totally non-dextral).

Group differences were assessed at baseline and follow-up
using independent group Student’s t-tests or w2-tests,
whereas longitudinal changes between the baseline and
follow-up time points in each group were examined using
paired Student’s t-tests. We used permutation statistics
(number of permutations ¼ 5000) via the Randomise tool in
FSL with family-wise error correction (po0.05). We also
employed threshold-free cluster enhancement in FSL (Smith
and Nichols, 2009) to eliminate the need for arbitrary
smoothing and cluster threshold criteria. Mean FA within
significant clusters was exported to SPSS to examine in
relation to clinical and metabolic measures (using a cutoff
value of po0.05; two-tailed) using either Pearson’s product
moment or Spearman’s rank (in the case of non-normally
distributed data) correlations.

DTI Procedures
MR imaging exams were conducted at the North Shore
University Medical Center on a General Electric 3-T wholebody superconducting imaging system. All scans were
reviewed by a radiologist for gross anatomic pathology that
would preclude participation in this study. Scans were also
reviewed by a member of the research team and scans with
significant artifacts were repeated. A total of 36 DTI
volumes were obtained from each subject that included
31 volumes with diffusion gradients applied along 31 nonparallel directions with b ¼ 1000 s/mm2 and 5 volumes
without diffusion weighting (b ¼ 0). Each volume consisted
of 51 contiguous 2.5-mm axial slices acquired parallel to the
anterior–posterior commissural line using a ramp-sampled,
spin-echo, single-shot echo-planar imaging method
(TR ¼ 14 000 ms, TE ¼ min, matrix ¼ 128  128, FOV ¼ 240
mm).

Image Processing and Tractography
Image processing was conducted using TBSS (Smith et al,
2006) within the Functional Magnetic Resonance Imaging of
the Brain Library (Jenkinson et al, 2012). Each subject’s DTI
data were aligned to the first b ¼ 0 volume, which was
acquired without diffusion weighting, to correct eddycurrent distortion, and the b-vector table for each
participant was adjusted accordingly. FA maps (radial
diffusivity (RD) and axial diffusivity (AD) maps) were
calculated for each voxel in the brain for all study
participants using DTIFIT, part of FSL’s diffusion toolbox.
Each image was then non-linearly transformed using FSL’s
non-linear image registration tool into FMRIB58 FA
Neuropsychopharmacology

RESULTS
The groups did not differ significantly in distributions of
age, sex, handedness, smoking status, height, weight,
education, or the number of weeks between the baseline
and follow-up scans (Table 1). Total BPRS scores decreased
significantly from the baseline to the follow-up MR imaging
exam (t ¼ 9.04, df ¼ 31, po0.001) but no significant changes
in negative symptoms (p40.05) were evident. There were
significant increases in cholesterol (t ¼  3.13, df ¼ 20,
p ¼ 0.003) and LDL (t ¼  2.81, df ¼ 30, p ¼ 0.009) but no
significant changes in HDL (p40.05) across the clinical
trial. As expected, there were significant increases in body
mass index from baseline to 12 weeks (t ¼  7.07, df ¼ 32,
po0.001).
Investigation of longitudinal changes using TBSS revealed
seven regions within the white matter skeleton, where FA
decreased significantly from baseline to the follow-up scan
among patients (Figures 1 and 2). The size of these clusters
ranged from 5 to 171 voxels (see Table 2) reflecting, on
average, a 4% reduction in FA (SD ¼ 2.5%; range ¼  0.1 to
 9.5%) across these seven regions. Individual datapoints
representing the average reduction in FA across the two
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Table 1 Baseline Sample Characteristics
First-episode patients (N ¼ 35)

Healthy volunteers (N ¼ 35)

df

Test statistic

P-value

21.5 (4.6)

21.8 (4.8)

68

t ¼ 0.26

NS

26 M/9 F

26 M/9 F

1

w2 ¼ 0

NS

Laterality quotient

0.71 (0.43)

0.70 (0.47)

67

t ¼  0.04

NS

Education (years)

12.6 (1.8)

12.9 (2.5)

67

t ¼ 0.46

NS

Height (inches)

67.6 (3.2)

68.6 (4.0)

68

t ¼ 1.14

NS

Weight (pounds)

144 (24)

161 (37)

70

U ¼ 469

NS

20

6

1

w2 ¼ 3.19

NS

12.5 (0.90)

12.4 (0.91)

68

t ¼  0.19

NS

Age (years)
Sex (M/F)

Smokers (%)
Scan interval (weeks)

Notes: Data are presented as mean±SD in parentheses, unless otherwise indicated. There were data missing for the following variables: years of education (1 patient)
and laterality quotient (1 patient).

Figure 1 Significant fractional anisotropy reductions (in blue) Following 12 weeks of antipsychotic treatment in patients overlaid onto the TBSS skeleton.
Note: for better visualization, significant clusters are ‘thickened’ (in red) using the ‘TBSS_fill’ script.’

Figure 2 Individual changes in average fractional anisotropy across seven
regions in patients (a) surviving family-wise error correction in TBSS from
baseline to follow-up and corresponding changes within the average of
these regions in healthy volunteers (b). Note: red line indicates mean
change in both groups.

time points for patients and healthy volunteer individuals is
provided in Figure 2. Additional analyses indicated that
among patients, AD decreased (t ¼ 4.32, df ¼ 34, po0.001)
and RD increased (t ¼  6.07, df ¼ 34, po0.001) across
the average of these regions (individual regions are
presented in Tables 2 and 3 for patients across the two
time points). Significant (po0.05) changes in FA, RD, and
AD across the average of the regions were evident
among patients treated with either risperidone or aripiprazole. In contrast, among healthy volunteers there was, on

average, a non-significant  0.04% (SD ¼ 3.3%) change in
FA across the average of these seven regions (range ¼  5.3
to 6.3%); moreover, no significant changes in AD or RD
across these regions were evident among healthy volunteers
(po0.05).
The single parietal and six occipital clusters were
subsequently used as seed regions in probabilistic
tractography. These analyses revealed that the parietal
lobe cluster comprised the tapetum, traversing the
splenium of the corpus callosum and extending toward
the temporal lobe. Regions comprising the occipital clusters
that differed across time points approximated posterior
sections of the inferior longitudinal fasciculus/forceps
major and possibly the inferior longitudinal fasciculus,
and extended from the occipital region through the
temporal lobe.
Given the lack of hypotheses regarding the correlates of
changes in specific white matter regions and to minimize
type-I error, we examined changes in clinical and metabolic
measures in relationship to the average decrease in FA
across the seven regions from the baseline to the follow-up
scans. Greater reductions in FA correlated significantly with
increases in LDL values (r ¼  0.42, df ¼ 29, p ¼ 0.019; see
Figure 3) and, more specifically, RD (r ¼ 0.43, df ¼ 29,
p ¼ 0.016), but not AD (p40.05). There was no significant
correlation between changes in FA, RD, or AD and
body mass index (p40.05). Changes in either positive
or negative symptoms across the two time points did not
correlate significantly with average change in FA across the
time points.
Neuropsychopharmacology
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Table 2 Baseline and Follow-up Fractional Anisotropy Measures
in Patients Surviving Family-wise Error Correction in TBSS
Baseline

Follow-up

FMRIB58
coordinates
(X, Y, Z)

Cluster
size

0.568 (0.064)

0.545 (0.061)

20,  57, 42

64

Parietal lobe
Cluster 1
Occipital lobe
Cluster 2

0.651 (0.046)

0.632 (0.050)

31,  68, 5

171

Cluster 3
Cluster 4

0.401 (0.080)
0.452 (0.064)

0.377 (0.077)
0.430 (0.063)

26,  83, 1
32,  78, 1

35
30

Cluster 5
Cluster 6

0.514 (0.065)
0.524 (0.056)

0.491 (0.066)
0.503 (0.055)

21,  85, 11
35,  70, 5

27
21

Cluster 7

0.522 (0.055)

0.509 (0.048)

22,  85, 5

5

Table 3 Baseline and Follow-up Axial and Radial Diffusivity
Measures in Patients within Regions that Demonstrated Significant
FA Reductions from Baseline to Follow-Up
Baseline

Follow-up

df

Test statistic

P-value

1.288 (0.082)

1.267 (0.081)

34

t ¼ 3.03

0.005

Cluster 2
Cluster 3

1.434 (0.082)
1.086 (0.077)

1.412 (0.073)
1.076 (0.070)

34
34

t ¼ 3.11
t ¼ 1.22

0.004
NS

Cluster 4
Cluster 5

1.093 (0.067)
1.308 (0.115)

1.079 (0.079)
1.282 (0.103)

34
34

t ¼ 1.88
t ¼ 3.18

0.069
0.003

Cluster 6
Cluster 7

1.174 (0.093)
1.283 (0.118)

1.156 (0.083)
1.279 (0.113)

34
34

t ¼ 2.27
t ¼ 0.43

0.030
0.670

Parietal lobe
Cluster 1

0.484 (0.054)

0.505 (0.052)

34

t ¼  5.12

o0.001

Occipital lobe
Cluster 2

0.430 (0.047)

0.446 (0.051)

34

t ¼  4.42

o0.001

Cluster 3
Cluster 4

0.585 (0.060)
0.531 (0.047)

0.605 (0.059)
0.548 (0.050)

34
34

t ¼  4.55
t ¼  3.28

o0.001
0.002

Cluster 5
Cluster 6

0.553 (0.054)
0.495 (0.047)

0.570 (0.053)
0.509 (0.047)

34
34

t ¼  4.13
t ¼  3.44

o0.001
0.002

Cluster 7

0.484 (0.054)

0.557 (0.044)

34

t ¼  2.12

0.041

Axial diffusivity
Parietal lobe
Cluster 1
Occipital lobe

Radial diffusivity

Note: Units are 10  3 mm2/s.

We investigated the potential effects of substance use on
the observed findings. Patients with a lifetime substance
use/dependence diagnosis demonstrated significant reductions in FA (t ¼ 6.00, df ¼ 17, po0.001) and AD (t ¼ 3.22,
df ¼ 17, p ¼ 0.005), as well as increases in RD (t ¼  3.45,
df ¼ 17, p ¼ 0.003) across the two time points. Similarly,
patients without a lifetime substance use/dependence
diagnosis also demonstrated significant changes across the
two time points with overall reductions in FA (t ¼ 7.02,
df ¼ 16, po0.001) and AD (t ¼ 2.80, df ¼ 16, p ¼ 0.013), with
increases in RD (t ¼  5.43, df ¼ 16, po0.001). Moreover,
significant (po0.05) reductions in FA and AD, as well as
increases in RD, were evident across the two time points in
the subgroup of patients without any abuse or dependence
in the month preceding the baseline scan (the only
subgroup large enough for analysis).
Neuropsychopharmacology

Figure 3 Scatterplot of changes in average fractional anisotropy and
low-density lipoprotein in patients following 12 weeks of antipsychotic
treatment.

DISCUSSION
Our DTI study, performed in the context of a double-blind,
randomized, controlled treatment trial, provided a unique
opportunity for clarifying the potential effects of antipsychotics on white matter integrity in patients experiencing a
first episode of psychosis early in the course of illness and
before extensive pharmacologic intervention. Our results
suggest that reductions in FA, a putative measure of white
matter integrity, are evident in parietal and occipital regions
following B12 weeks of atypical antipsychotic treatment.
Study strengths include the use of a conservative tractinvariant analysis of FA data, family-wise error correction,
limited treatment history of patients before baseline
scanning, controlled antipsychotic treatment between scans,
and the use of a healthy volunteer group well matched to
patients for age, sex, and interscan interval. The lack of any
significant FA changes among healthy volunteers who were
scanned over the same time period supports the reliability
of the DTI measurements.
Our findings are broadly consistent with prior work over
a similar timeframe using structural imaging (Lieberman
et al, 2005) and other longitudinal morphometric studies
investigating white matter volume changes related to
antipsychotic treatment. In one of the largest studies,
involving a total of 674 MR imaging scans and yielding an
average of 3 scans per patient over the course of 7.2 years,
Ho et al (2011) reported progressive white matter volume
reductions among patients with schizophrenia, who received the greatest amount of antipsychotic treatment.
Similarly, both Molina et al (2005) and Girgis et al (2006)
reported white matter volume reductions in treatment-naive
patients following 2 years and 6 weeks of treatment with
risperidone, respectively. Notably, in these studies, white
matter volume increases were not evident among patients
and no white matter volume changes were observed in
healthy volunteers. Moreover, our findings also converge
with animal data, suggesting that administration of atypical
antipsychotics is associated with changes in the brain gray
and white matter in macaques treated with oral haloperidol
or olanzapine compared with a sham group over a 17- to 27month period (Dorph-Petersen et al, 2005).
Little in-vivo research has been directed at understanding
the relationship between antipsychotic treatment and
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changes in white matter integrity, as inferred by DTI
imaging, using a longitudinal design. Our findings converge
strongly, however, with those described by Wang et al
(2013) who reported that compared with 22 healthy
controls, there was a significant decrease in absolute FA
in the white matter in first-episode drug-naive patients with
schizophrenia after 6 weeks of antipsychotic treatment
that did not correlate with symptom reduction. In our
study, FA reductions were subtle and were most likely
detected through the use of a within-subjects design, thus
affording greater statistical power compared with crosssectional studies. In contrast, no FA increases were
observed in patients over the 12-week treatment period. It
is conceivable that microstructural white matter changes
may be related to metabolic changes associated with
antipsychotic treatment, as such changes have been
reported to occur among individuals with the metabolic
syndrome (Shimoji et al, 2013). For example, recent work
(Karlsson et al, 2013) suggests that obese individuals have
lower FA in brain regions associated with reward seeking
and appetite, and that FA was negatively associated with
body fat percentage.
There may be several additional explanations regarding
the observed FA reductions following antipsychotic treatment. Such reductions could be due to alterations in the
composition of glial cells, which have been strongly
implicated in several psychiatric disorders, including
schizophrenia (Blank and Prinz, 2013). Furthermore,
macaque data indicate that chronic antipsychotic treatment
was associated with a reduction in glial cell numbers
(Konopaske et al, 2008). Changes in white matter integrity
in association with antipsychotic treatment may be related
to specific alterations in macroglia and, in particular,
oligodendrocytes, which form the myelin sheath, and
together comprise the bulk of the white matter. In this
regard, it is noteworthy that myelin comprises primarily of
lipids, which have also been demonstrated to be affected by
antipsychotic treatment (Huang and Chen, 2005). The
finding of AD reductions and RD increases supports the
possibility that axonal and myelin-related properties of the
white matter (Song et al, 2002, 2003, 2005) may be altered
by antipsychotic medications, and thereby contribute to the
observed FA reductions. Moreover, changes in the expression of myelin basic protein, which have been linked to
antipsychotic use (Kimoto et al, 2011), may have also
contributed to the white matter changes observed herein.
In the current study, FA reductions in more posterior
regions, but not in anterior regions, were associated with
antipsychotic treatment. It is possible that longer exposure
to antipsychotics could be associated with changes in more
anterior regions. In addition, it is also conceivable that FA
alterations might already be evident within frontal and
temporal lobe regions among patients consistent with
neurobiological models of schizophrenia (Szeszko et al,
2005, 2008). It is noteworthy that a recent ultra-high field
(7 T) combined DTI and magnetization transfer imaging
study by Palaniyappan et al (2013) reported white matter
abnormalities in occipito-temporal regions in 17 clinically
stable patients with schizophrenia compared with that in 20
controls. These abnormalities were associated with impaired processing speed. Moreover, we reported previously
that compared with patients with schizophrenia, who did

not respond to antipsychotic treatment, those who did
respond had more pronounced abnormalities in the
occipital regions (Szeszko et al, 2012). Thus, we hypothesize
that occipital FA changes may be a potentially important
consideration in identifying treatment targets in schizophrenia.
Reductions in FA among patients were associated with
increases in LDL across the treatment trial. Although there
are limited data regarding the relationship between FA and
metabolic measures, our findings converge strongly with
cross-sectional data from Williams et al (2012) who
reported that higher LDL was associated with lower FA
among older healthy individuals below the clinical threshold for hyperlipidemia. Other data suggest that LDL levels
are associated with greater severity of cerebral white matter
changes on MR imaging (Crisby et al, 2010). Although
metabolic changes are typically associated with antipsychotic treatment, the underlying neurobiology regarding
concomitant brain changes is not well understood.
Approximately one-quarter of the sterol within the body
is localized to the brain (Dietschy and Turley, 2004) and is
considered a major constituent of myelin such that
cholesterol within oligodendrocytes has a key role in brain
maturation (Saher et al, 2005). It is unlikely that changes in
serum cholesterol directly impact metabolism of sterol
within the brain, given that such an exchange does not
occur across the blood–brain barrier (Björkhem and
Meaney, 2004). For the maintenance of adequate brain
cholesterol, the excess is excreted through cytochrome
P-450-generated oxysterol 24S-hydroxycholesterol, thus
permitting crossing of the blood–brain barrier (Björkhem
and Meaney, 2004). Antipsychotics have been demonstrated
to upregulate genes involved in cholesterol biosynthesis
with subsequent changes in gene expression followed by
enhanced HMGCR (3-hydroxy-3-methylglutaryl-coenzyme
A reductase) enzyme activity and concomitant increases in
cellular cholesterol (Ferno et al, 2005). Moreover, changes
in the balance of cholesterol between the brain and other
body compartments may be associated with concomitant
alterations in sterol within the CNS, thereby affecting white
matter integrity (Dietschy and Turley, 2001).
There were a number of limitations to our study and
other possible explanations regarding the study findings
that should be acknowledged. Although patients were
treated for a relatively brief period of time, we cannot
definitively rule out disease progression given the lack of an
untreated patient group, and because patients are typically
ill for 1–2 years before initiating treatment (Robinson et al,
2006). In addition, we did not investigate the potential
effects of long-term antipsychotic treatment on the brain;
however, our data are consistent with findings of lower FA
throughout the white matter in DTI studies of chronically
treated patients (Lim et al, 1999; Friedman et al, 2008). In
addition, we did not collect cardiometabolic data in healthy
volunteers and we acknowledge that smoking patterns,
which have been reported to alter measures of white matter
integrity (Gons et al, 2011; Paul et al, 2008), could
conceivably affect the findings in patients reported herein,
although the proportion of smokers in each group did not
differ significantly. Lower FA could also be related to
elevated body mass index (Xu et al, 2013; Stanek et al, 2011)
and diabetes mellitus (Kodl et al, 2008); however, none of
Neuropsychopharmacology
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the subjects in our study had or developed diabetes during
the treatment trial. A prior history of substance use among
patients should also be noted as a possible limitation,
although post-hoc analyses did not identify any effect of
substance abuse/dependence on the observed FA reductions. Lastly, it should be acknowledged that several studies
(Jones et al, 2005; Voineskos et al, 2010) reported that
elderly patients with schizophrenia do not differ from
healthy volunteers on some measures of white matter
integrity, including those investigated in the current study.
Thus, despite prior antipsychotic medication exposure,
some patients may be resistant to the effects described in
the current study.
In sum, we report reductions in white matter integrity
after antipsychotic treatment in individuals experiencing a
first episode of psychosis. Additional studies are needed to
clarify the potential long-term effects of antipsychotics on
white matter integrity and the identification of potential
mechanisms to reverse such changes.
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